CHEK2 and cancer: Combining these studies, together with further integration with cancer cohorts and population databases, such as UK BioBank, FinnGen, and All of Us, has the potential to provide yet stronger evidence to enable more definitive classifications of clinical CHEK2 variants and provide patient-level information for assessing variant-specific risk.78